Newswise Human genomics holds promise for prevention and tailored treatment of chronic illnesses. At the same time, ethnic minorities, who bear a disproportionate burden of chronic illnesses, take part in genomics research at low rates. When Aaron Buseh, associate professor of nursing, began talking to members of the African American community about their reluctance to take part in genetic research, two cases were mentioned over and over again the Tuskegee syphilis experiments and Henrietta Lacks. In both cases, African American subjects were involved in research without ever being informed about the goals or results, being told about potentially harmful consequences, benefiting from the research or even giving informed consent. The 40 years of Tuskegee research abuses were exposed in the media in 1972. A 2010 book, The Immortal Life of Henrietta Lacks, outlined how others made huge profits from the HeLa line of cancer cells developed from Lackss genetic material, while her family lived in poverty. For the past three years, the Community Engagement in Genetics/Genomics Project, led by Buseh, co-principal investigator Professor Sandra Underwood, Professor Patricia Stevens and a group of researchers from the College of Nursing, has been looking at the issues involved and identifying community-engagement strategies to … Continue reading →

First dog on Oahu gets stem cell therapy A 13-year-old dog who was barely able to walk is back on his paws thanks to stem cell therapy. Before the treatment Kumba suffered from arthritis so bad he c... By: Joem Costes … Continue reading →

Berlin, Germany, June 20, 2013 - MagForce AG (Frankfurt, Entry Standard, XETRA: MF6), a leading medical device company in the field of nanomedicine focused on oncology, announced today that the two different existing share classes have been prematurely merged, effective June 20, 2013. The new shares issued in the context of the capital increase early 2013 with ISIN DE000A1R1KE3 (WKN A1R1KE) and the old shares with ISIN DE000A0HGQF5 (WKN A0HGQF) will immediately be traded under the security details of the old shares: ISIN DE000A0HGQF5 (WKN A0HGQF). New shares have been suspended for trading accordingly on the morning of June 20, 2013. It is expected that shares will be available for trading late in the day under WKN A0HGQF. About MagForce AG MagForce AG is a leading medical device company in the field of nanomedicine in oncology. The Company`s proprietary, NanoTherm therapy, enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. NanoTherm, NanoPlan, and NanoActivator(TM) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator(TM) are trademarks of MagForce AG in selected countries. For more information, please … Continue reading →